Prezista gets EU approval.
D017326:Clinical Trials, Phase III as Topic; D000069454:Darunavir; D017277:Drug Approval; D005060:Europe; D005062:European Union; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D013449:Sulfonamides / Q000592:standards / Q000627:therapeutic use*
D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir